Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -22.33% is 88% above its 5-year average of -184.26%, near the high end of its 5-year range (-600.42%–-22.33%).
76.89% above its 12-month average of -96.60%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -6.61%.
RETURN ON ASSETS (ROA)
-22.33%
RETURN ON ASSETS (ROA) AVG TTM
-96.60%
RETURN ON ASSETS (ROA) AVG 3Y
-247.71%
RETURN ON ASSETS (ROA) AVG 5Y
-184.26%
RETURN ON ASSETS (ROA) AVG 10Y
-142.70%
RETURN ON ASSETS (ROA) AVG 15Y
-90.87%
RETURN ON ASSETS (ROA) AVG 20Y
-104.80%
CURRENT VS TTM AVG
+76.89%
CURRENT VS 3Y AVG
+90.99%
CURRENT VS 5Y AVG
+87.88%
CURRENT VS 10Y AVG
+84.35%
CURRENT VS 15Y AVG
+75.43%
CURRENT VS 20Y AVG
+78.69%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+30.74%
vs the sector median at left
SELLAS Life Sciences Group, Inc.
Market Cap
$2.13B
Return on Assets (ROA)
-22.33%
TTM Avg
-96.60%
3Y Avg
-247.71%
5Y Avg
-184.26%
Market Cap
$2.13B
Return on Assets (ROA)
-22.09%
TTM Avg
-8.08%
3Y Avg
-39.70%
5Y Avg
-49.84%
Market Cap
$2.16B
Return on Assets (ROA)
-53.05%
TTM Avg
-52.17%
3Y Avg
-43.79%
5Y Avg
-37.43%
Market Cap
$2.11B
Return on Assets (ROA)
7.23%
TTM Avg
5.94%
3Y Avg
5.72%
5Y Avg
5.23%
Market Cap
$2.09B
Return on Assets (ROA)
-75.40%
TTM Avg
-31.99%
3Y Avg
-46.60%
5Y Avg
-53.88%
Market Cap
$2.07B
Return on Assets (ROA)
-11.31%
TTM Avg
-8.55%
3Y Avg
-34.29%
5Y Avg
-31.66%
Market Cap
$2.20B
Return on Assets (ROA)
-12.82%
TTM Avg
-15.67%
3Y Avg
-7.42%
5Y Avg
-2.36%
Market Cap
$2.06B
Return on Assets (ROA)
-35.27%
TTM Avg
-37.23%
3Y Avg
-38.20%
5Y Avg
-46.02%
Market Cap
$2.07B
Return on Assets (ROA)
-38.42%
TTM Avg
-32.16%
3Y Avg
-31.63%
5Y Avg
-27.96%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | $2.13B | -22.33% | -96.60% | -247.71% | -184.26% |
| GeneDx Holdings Corp. (WGS)vs › | $2.13B | -22.09% | -8.08% | -39.70% | -49.84% |
| Pharvaris N.V. (PHVS)vs › | $2.16B | -53.05% | -52.17% | -43.79% | -37.43% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 7.23% | 5.94% | 5.72% | 5.23% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.09B | -75.40% | -31.99% | -46.60% | -53.88% |
| Alvotech (ALVO)vs › | $2.07B | -11.31% | -8.55% | -34.29% | -31.66% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.20B | -12.82% | -15.67% | -7.42% | -2.36% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | -35.27% | -37.23% | -38.20% | -46.02% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | -38.42% | -32.16% | -31.63% | -27.96% |
| Vericel Corporation (VCEL)vs › | $2.06B | 4.82% | 2.89% | -0.31% | -0.49% |
ROA
-22.3%
ROE
-23.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -34.29% |
| 2024-12-31 | -158.92% |
| 2023-12-31 | -600.42% |
| 2022-12-31 | -197.21% |
| 2021-12-31 | -78.33% |
| 2020-12-31 | -36.39% |
| 2019-12-31 | -116.15% |
| 2018-12-31 | -163.58% |
| 2017-12-31 | -70.85% |
| 2016-12-31 | -35.78% |
| 2015-12-31 | -77.79% |
| 2014-12-31 | -45.48% |
| 2013-12-31 | -87.16% |
| 2012-12-31 | -63.60% |
| 2011-12-31 | -37.09% |
| 2010-12-31 | -160.42% |
| 2009-12-31 | -294.10% |
| 2008-12-31 | -138.75% |
| 2007-12-31 | -90.48% |
| 2006-12-31 | -120250.00% |
